

1 **Proof-of-concept: SCENTinel 1.1 rapidly** 2 **discriminates COVID-19 related olfactory** 3 **disorders**

4
5 Stephanie R. Hunter^{1†}, Mackenzie E. Hannum^{1†}, Robert
6 Pellegrino¹, Maureen A. O’Leary¹, Nancy E. Rawson¹, Danielle
7 R. Reed¹, Pamela H. Dalton¹, Valentina Parma^{1,2*}
8

9 ¹ Monell Chemical Senses Center, Philadelphia, PA

10 ² Department of Psychology, Temple University, Philadelphia, PA

11 [†] Equal contributions
12

13

14 ***Correspondence:**

15

16 Valentina Parma, PhD

17 Monell Chemical Senses Center

18 3500 Market Street

19 Philadelphia, PA 19143

20 Email: vparma@monell.org

21

22 **Keywords:** Anosmia, hyposmia, parosmia, phantosmia, prediction, smell test
23

24 **Abstract**

25 It is estimated that 20-67% of those with COVID-19 develop olfactory disorders, depending on
26 the SARS-CoV-2 variant. However, there is an absence of quick, population-wide olfactory tests
27 to screen for olfactory disorders. The purpose of this study was to provide a proof-of-concept
28 that SCENTinel 1.1, a rapid, inexpensive, population-wide olfactory test, can discriminate
29 between anosmia (total smell loss), hyposmia (reduced sense of smell), parosmia (distorted odor
30 perception), and phantosmia (odor sensation without a source). Participants were mailed a
31 SCENTinel 1.1 test, which measures odor detection, intensity, identification, and pleasantness,
32 using one of four possible odors. Those who completed the test (N = 381) were divided into
33 groups based on their self-reported olfactory function: quantitative olfactory disorder (anosmia
34 or hyposmia, N = 135), qualitative olfactory disorder (parosmia and/or phantosmia; N = 86), and
35 normosmia (normal sense of smell; N = 66). SCENTinel 1.1 accurately discriminates
36 quantitative olfactory disorders, qualitative olfactory disorders, and normosmia groups. When
37 olfactory disorders were assessed individually, SCENTinel 1.1 discriminates between hyposmia,
38 parosmia and anosmia. Participants with parosmia rated common odors less pleasant than those
39 without parosmia. We provide proof-of-concept that SCENTinel 1.1, a rapid smell test, can
40 discriminate quantitative and qualitative olfactory disorders, and is the only direct test to rapidly
41 discriminate parosmia.

42

43

44 Introduction

45 Prior to March 2020, a nationally representative survey in 3,603 individuals reported
46 more than 20% of individuals experienced olfactory disorders over the course of their lifetime
47 [1]. These olfactory disorders, broadly classified, include quantitative and qualitative olfactory
48 disorders, which can occur in isolation or together [2,3]. Quantitative olfactory disorders are
49 those where the perceived intensity of the odor is diminished and include anosmia (e.g., total
50 smell loss) and hyposmia (e.g., reduced sense of smell). Qualitative olfactory disorders are
51 disorders where the perceived quality or identity of an odor is changed, including parosmia (e.g.,
52 distorted odor perception with a known source) and phantosmia (e.g., odor sensation without an
53 odor source). These olfactory disorders have a large negative impact on overall quality of life
54 [4].

55 The prevalence of quantitative olfactory disorders has increased dramatically due to the
56 COVID-19 pandemic, where sudden loss of smell is a specific symptom [5]. As of June 2022,
57 there have been more than 86 million reported cases of COVID-19 in the United States alone [6].
58 Of those who contract COVID-19, about 50% self-report losing their sense of smell [7]. While
59 most of these individuals fully recover their sense of smell within three weeks [8–11], about 10-
60 15% have persistent smell loss for more than one month [8,12]. Thus, millions of Americans are
61 now at risk of experiencing chronic smell loss due to COVID-19. These prevalence estimates of
62 smell loss from COVID-19 remain uncertain, however, because of symptomatic differences in
63 SARS-CoV-2 variants (e.g., smell loss is not as prevalent with the omicron variant compared to
64 the previous variants) [7,13,14]. Furthermore, people are generally not proficient at subjectively
65 assessing their smell ability [1,7,15–18]. Prior research has shown that directly testing olfactory
66 function provides a better representation of the prevalence of smell loss compared to self-report

67 [7]. Currently validated smell tests, such as UPSIT [16,19–24], Sniffin’ Sticks [25–27], or the
68 NIH Toolbox Odor Identification Test [28], among others, are sensitive at accurately identifying
69 quantitative olfactory disorders, including anosmia and hyposmia. However, these tests lack
70 suitability for population-wide surveillance of smell function, especially during the COVID-19
71 pandemic, due to their odor delivery method, increased cost and time to execute, and/or because
72 the test cannot be self-administered.

73 To address these shortcomings in olfactory testing, we created the SCENTinel Rapid
74 Smell Test [29]. The first version of the test, SCENTinel 1.0, is a self-administered test that uses
75 flower as a target odor to assess odor detection (“select the patch with the strongest odor”), odor
76 intensity (“rate the intensity of the odor” using a visual analog scale from 1–100), and odor
77 identification (“identify the odor” when given four picture/label options). To enable the use of
78 SCENTinel as a rapid test of smell function, accuracy criteria were established: odor detection
79 and odor identification answers are coded as correct or incorrect and odor intensity uses a cutoff
80 of 20 to determine normal smell function (i.e., normosmia), based on a previous study by Gerkin
81 et al [5]. These three subtests are then combined to create an overall score, which was previously
82 found to differentiate between people self-reporting anosmia from normosmia [29].

83 Many of the direct approaches to assess olfactory function only focus on quantitative
84 smell disorders and there remains a dearth of direct tests that discriminate for qualitative
85 olfactory disorders, including parosmia and phantosmia. Often, qualitative olfactory disorders
86 are diagnosed through subjective ratings from questionnaires and/or patient history obtained
87 through interviews [30–35]. This reliance on self-report leaves estimates of qualitative olfactory
88 disorders likely underrepresented, only diagnosed when individuals consult specialists. However,
89 even with subjective reports, qualitative olfactory disorders are present in more than half of those

90 reporting smell impairment [36–38], and distinct features of parosmia and phantosmia are
91 beginning to surface [31]. Parosmia encompasses distortions of a known odor, often
92 experiencing pleasant odors as unpleasant or vice versa [39], so one way to assess parosmia
93 directly is to have participants rate the pleasantness of two oppositely valenced odors (i.e., a
94 pleasant and unpleasant odor). This procedure creates a hedonic score, such that those with
95 parosmia have a lower hedonic score than those with normosmia, assuming those with parosmia
96 would rate the pleasant odor as unpleasant. Liu and colleagues successfully employed this
97 technique to classify two patients with parosmia [27]. Directly testing for parosmia may still
98 prove difficult, because parosmia reports are not consistent across all odors. Odors that are
99 frequently associated with parosmia include coffee, meats, onion, garlic, and chocolate [2,31,40],
100 yet the direct cause for the odor-specificity remains to be understood. Individuals with odor-
101 specific parosmia may only be detected with direct smell tests if the distorted odor is used in the
102 test, and therefore, multiple odor versions are needed. Overall, there is a pressing need to directly
103 measure quantitative and qualitative olfactory disorders in a fast and inexpensive way to enable a
104 better assessment of the magnitude of smell impairments in the population. Once validated
105 against gold-standards and normed, such tests may help to diagnose diseases where smell loss is
106 a symptom (including head trauma [41–43], neurodegenerative diseases [44–46], and viral
107 illness [47]), and help evaluate the impact of treatments and therapies for those living with
108 olfactory disorders.

109 Here, we extend SCENTinel 1.0 to a new version, SCENTinel 1.1, with the goal to
110 discriminate between quantitative and qualitative olfactory disorders. Using the rationale from
111 Liu et al. [27], we include a hedonic score subtest to discriminate qualitative olfactory disorders
112 population-wide. Specifically, after participants complete the odor detection, intensity, and

113 identification subtests, they will rate the pleasantness of two oppositely valenced odors (the
114 actual odor on the SCENTinel test received, and an imagined, universally unpleasant odor) to
115 create a hedonic score to directly measure parosmia and phantosmia. Using two odors enables a
116 common anchor between the hedonic scores to account for varying scale usage. Additionally,
117 SCENTinel 1.1 includes four target odor versions: flower (the same odor in SCENTinel 1.0),
118 bubblegum, coffee, and caramel popcorn (Supplementary Table S1), enabling SCENTinel to be
119 used for repeat testing (12 different odor/placement combinations) and to capture potential odor-
120 specific olfactory symptoms.

121 In the present study, we sought to test the ability of SCENTinel 1.1 to discriminate
122 different smell disorders through three aims. First, we aim to validate the ability of SCENTinel
123 1.1 (with multiple target odors) to discriminate between those with normosmia and anosmia,
124 based on the original model developed with SCENTinel 1.0 (with one target odor) [29]. We
125 hypothesize that SCENTinel 1.1 will discriminate between participants with normosmia and
126 anosmia similarly to that reported in SCENTinel 1.0.

127 Second, we aim to determine SCENTinel 1.1's accuracy in distinguishing between
128 quantitative (anosmia and hyposmia) and qualitative (parosmia and phantosmia) olfactory
129 disorders. Specifically, we expect those with quantitative olfactory disorders will rate the odor
130 intensity as low or absent and may not be able to distinguish the odor stimulus, therefore unable
131 to meet the accuracy criteria for odor detection, intensity and, likely, identification if they are
132 anosmic or severely hyposmic. Those with qualitative olfactory disorders may correctly detect
133 the odor and rate the intensity >20, but its quality may be distorted, so we hypothesized that they
134 would perform better overall on SCENTinel 1.1 compared to those with quantitative disorders,
135 but their odor identification ability might be jeopardized.

136 Finally, we aim to explore whether assessing odor pleasantness can accurately
137 discriminate those with parosmia. Experiencing distorted odors is often reported as an unpleasant
138 experience [39], therefore we hypothesized that those with qualitative olfactory disorders (i.e.,
139 parosmia) would report a lower hedonic score for common odorants included in SCENTinel 1.1
140 than those without distortion (e.g., people with hyposmia or normosmia).

141 **Materials & Methods**

142 The materials, procedures, hypotheses, and pre-analysis plan were pre-registered and are
143 publicly available in the Open Science Framework Repository [48].

144 **SCENTinel 1.1**

145 The SCENTinel 1.1 test card contains three patches created with Lift'nSmell technology
146 (Scentisphere, Carmel, NY), of which only one patch contains a target odor and the other two are
147 blank. SCENTinel 1.1 includes four subtests: odor detection accuracy (correct/incorrect); odor
148 intensity (above/below a cutoff of 20, or continuous value depending on the analysis); odor
149 identification among 4 given options (correct/incorrect) or, if the first response is incorrect,
150 among the 3 remaining options (correct/incorrect); and a hedonic score (pleasantness rating of an
151 unpleasant imagined odor (vomit) – pleasantness rating of the target odor on the SCENTinel test;
152 procedure outlined in Supplementary Fig. S1). The target odor on SCENTinel 1.1 is one of four
153 possible odors, such that participants received a SCENTinel 1.1 test with either a flower, a
154 coffee, a bubblegum, or a caramel popcorn target odor. However, note that there is only one odor
155 on each SCENTinel test. Therefore, participants smelled only one of the four possible odors. All
156 odors were from Givaudan (Cincinnati, OH; see Supplementary Table S1 for catalog numbers)

157 and were designed to be iso-intense at an intensity of 80 on a scale of 0 to 100, confirmed via
158 pilot testing.

159 **Participants**

160 Participants were recruited through two exclusive Facebook groups (“Covid-19 Smell
161 and Taste Loss” and “AbScent Parosmia and Phantosmia Support” hosted by AbScent, a charity
162 serving individuals with smell and taste disorders based in the UK), which were open to those
163 suffering from olfactory disorders due to COVID-19 and their family and friends. Interested
164 participants were instructed to complete an online survey to determine eligibility. Those who
165 reside in the United States, between 18-75 years old, and have access to a smart device or
166 computer were eligible for this study.

167 Of the 1290 individuals who completed the eligibility survey, 733 were eligible and were
168 mailed a SCENTinel 1.1 test on a first-come, first-served basis, and 512 participants completed
169 the test (response rate: 70%; see Figure 4 for a schematic overview). Participants were excluded
170 if they reported smell loss unrelated to COVID-19 (N = 19), illogical self-reported olfactory
171 disorders (e.g., selected both anosmia and hyposmia or anosmia and parosmia; N = 30), self-
172 reported full recovery at the time of the SCENTinel test (N = 2), a negative COVID-19 test (i.e.,
173 no confirmed COVID-19 diagnosis; N = 57), undiagnosed smell loss (i.e., reported having a
174 current olfactory disorder other than anosmia, hyposmia, parosmia, or phantosmia; N = 11), or
175 incomplete data (N = 12). Ultimately, 348 participants with a smell disorder from laboratory-
176 confirmed COVID-19 and 33 participants with normosmia were included in the final analyses.
177 Participants were assigned to smell groups based on their response to the question outlined in
178 Figure 4: 135 participants had only anosmia or hyposmia (quantitative olfactory disorder,
179 referred to as **quantitative OD group**), 86 had only parosmia or phantosmia (qualitative

180 olfactory disorder, referred to as **qualitative OD group**), and 94 reported having both
181 quantitative and qualitative olfactory disorders (mixed), and 33 participants indicated that they
182 did not have any issues with their sense of smell (normosmia). Because there was only a small
183 population with normosmia in the Facebook groups, as expected given the nature of the group,
184 we added a convenience sample of 33 participants with normosmia who met the inclusion
185 criteria for this study. These additional participants completed SCENTinel 1.1 for a separate
186 study, recruited via fliers around the Philadelphia, PA area. The separate and current studies are
187 both part of the same, multi-site, IRB protocol, which was approved by the University of
188 Pennsylvania Institutional Review Board (protocol no. 844425) and complied with the
189 Declaration of Helsinki.

190 Odor placement and target odor were equally distributed among groups in participants
191 who were included in the final analyses (Supplementary Table S5).

192 **Procedure**

193 Eligible participants received one SCENTinel 1.1 test, containing one of the four
194 potential odors. Upon receiving the SCENTinel 1.1 test, participants scanned a QR code or
195 entered a URL into a web browser that brought them to a REDCap survey [49]. Participants first
196 provided consent using the approved online consent form. They then answered demographic
197 information (age, gender, race, and ethnicity) and indicated whether they had issues with their
198 smell or taste at the time of taking the test. If they answered yes, they indicated in a check-all-
199 that-apply question (Figure 4) whether they 1) cannot smell anything (anosmia), 2) can smell
200 some odors but they are weaker than usual (hyposmia), 3) can smell strong odors but they smell
201 differently than they typically smell (parosmia), 4) smell things that are not there, such as smoke
202 when there is no fire (phantosmia), 5) other. Participants were then instructed to lift and smell

203 each patch on the SCENTinel 1.1 card, one at a time, from left to right, and 1) select which patch
204 smells the strongest (odor detection), 2) rate how intense the odor was on a 100-point visual
205 analog scale (odor intensity), and 3) identify the odor out of four possible options (odor
206 identification). If they identified the odor incorrectly the first time, they were given a second
207 chance (three alternative-forced choice paradigm). Binary responses (correct/incorrect) to these
208 subtests (odor detection, odor intensity, and odor identification; note: odor intensity subtest had a
209 cut off of 20 out of 100) were used to calculate participants' overall score specified in a previous
210 publication [29]. Potential response strategies are outlined in Table 1. Participants then rated the
211 pleasantness of the odor on the card and the pleasantness of the smell of vomit (by imagining the
212 smell) using a 100-point visual analog scale anchored with "Very Unpleasant" at 0 and "Very
213 Pleasant" at 100. These pleasantness ratings were used to calculate a hedonic score [from -100 to
214 100] by subtracting the rating of the pleasantness of the odor on the card and the rating of the
215 pleasantness of imagined vomit. The hedonic score was not included in the SCENTinel 1.1
216 overall score. Participants also rated the frequency at which they experienced distorted or
217 phantom odors in the past week using a 100-point visual analog scale from 0 - "Never" to 100 -
218 "All the time". These questions were similar to those used to measure parosmia in Liu et al [27].

219

220 [INSERT TABLE 1 HERE]

221 **Data Analysis**

222 This cross-sectional design included the between-subject factor "smell function" group
223 (quantitative OD, qualitative OD, normosmia; Figure 4) and the following within-subject factors:
224 meeting the accuracy criteria within SCENTinel 1.1 subtests (odor detection, intensity,
225 identification), overall score, as well as the new subtest, hedonic score. The intensity subtest had

226 a cut-off of 20 (out of 100) when calculating SCENTinel 1.1 overall score, but was analyzed as a
227 continuous measure (0 – 100) in the Bayes analysis and prediction model (described below) to
228 benefit from the full-scale variability of the ratings. In accordance with the preregistration [48],
229 we originally included a “mixed” group in the between-subject factor smell ability (Figure 4),
230 but this group showed no coherent pattern (similar to a recent study [31]) and was therefore
231 removed from the main analysis (see Supplementary Table S6). Demographics included in the
232 analyses were sex (male, female), race (white, non-white), and age (continuous). Due to the
233 unequal distribution of data across categories, we binarized race as white and non-white, which
234 included those who were American Indian or Alaska Native, Asian, Black or African American,
235 Hispanic or Latino, Native Hawaiian or Other Pacific Islander, and other.

236 The linear discriminant model (LDA), which discriminated those with anosmia from
237 normosmia in SCENTinel 1.0 [29], was prospectively validated with SCENTinel 1.1 participant
238 pool. Participants with anosmia (N = 51) and normosmia (N = 66) from SCENTinel 1.1 were
239 predicted with the prior model features - demographic variables (gender, age, ethnicity) as well
240 as the original SCENTinel 1.0 item scores (odor detection, intensity, identification). The receiver
241 operating characteristic (ROC) area under the curve (AUC) was calculated for the prospective
242 validation dataset (SCENTinel 1.1) and compared to the prediction from prior withheld dataset
243 (20% of the SCENTinel 1.0 data in the previous paper (AUC = 0.95)) [29].

244 Machine learning classification algorithms were applied to predict the ability of
245 SCENTinel 1.1 to discriminate quantitative OD, qualitative OD, and normosmia groups of
246 individuals greater than chance. Data were preprocessed using the procedures in our previous
247 publication [29]. Multiclass models using random forest, linear, and radial small vector machine,
248 regularized linear regression (Elastic net), and linear discriminant analysis (LDA) were

249 optimized with their respective tuning parameters using cross-validation. Cross-validation
250 (number = 10, repeat = 5) was performed on the training set (80% of the sample), and validation
251 was completed on the remaining, withheld data (20%). The model that provided the best
252 classification multi-class AUC on the withheld data was LDA, which we report and discuss in
253 the text. To look at specific olfactory disorders within quantitative and qualitative OD groups, a
254 separate LDA model was fit to predict those with parosmia, hyposmia, and anosmia.

255 Cutoff values were calculated with Youden's Index [50] for SCENTinel subcomponents
256 that significantly predicted normosmia from quantitative and qualitative olfactory disorders from
257 the machine learning classification algorithm. Youden's Index has previously been used to
258 determine cutoff values in olfactory tests for clinical populations [51].

259 A sequential Bayes factor design (SBFD) with maximal N, as suggested by Schönbrodt et
260 al. [52] was used to compare group performance between individual subtests of SCENTinel 1.1.
261 This SBFD design requires on average half the sample size compared with the optimal null
262 hypothesis testing fixed-n design, with comparable error rates [52]. The desired grade of relative
263 evidence for the alternative (H_1) versus the null (H_0) hypothesis is set at the following: $BF_{10} >$
264 100 (extreme evidence), $100 > BF_{10} > 30$ (very strong evidence), $30 > BF_{10} > 10$ (strong
265 evidence), $10 > BF_{10} > 3$ (substantial evidence), and $3 > BF_{10} > 1$ (anecdotal evidence). Based on
266 a Cohen's $d = 0.5$, we have specified a minimum sample size per group of $N_0 = 43$. To assess the
267 differences in accuracy among subtests, we have employed Bayesian and parametric tests for
268 equality of proportions with or without continuity correction. Planned contrasts were additionally
269 done among the broad smell groups (i.e., quantitative OD, qualitative OD, normosmia), and
270 among individual specific groups within each broad group (i.e., anosmia, hyposmia, parosmia).
271 Phantosmia was not included in the specific group assessment given the reduced number of

272 people with phantosmia, in line with the current prevalence estimates [31]. Results from the
273 SBFDF planned contrasts can be found in Supplementary Table S3.

274 We conducted an exploratory analysis to further investigate the hedonic ratings among
275 those with and without parosmia. Welch's two-sample t-test assessed differences in hedonic
276 score across the individual smell groups (i.e., hyposmia, normosmia, parosmia). Participants
277 were collapsed into two groups depending on their self-reports: parosmia and no parosmia.
278 Pearson's product-moment correlation assessed the relationship between the reported frequency
279 of parosmia events and the reported hedonic range for those with parosmia. A 2-way ANOVA
280 (independent variables: odor and parosmia group; random variable: participants) was conducted
281 to investigate if the hedonic score was different across the four odors used in SCENTinel 1.1.
282 Lastly, Welch's two-sample t-test assessed the overall difference in the odor and vomit rating
283 across parosmia groups.

284 All statistical analyses were conducted in the R Environment for Statistical Computing
285 [53].

286

287 Results

288 **SCENTinel 1.1 with the four target odor variations maintains accurate performance in** 289 **anosmia discrimination.**

290 To assess the validity of the original model [29], and the impact of the features included
291 in SCENTinel 1.1 (e.g., multiple odor versions), we prospectively verified the ability of the
292 SCENTinel 1.0 classification model to predict the performance of individuals with anosmia and
293 normosmia in a new sample of participants with COVID-19-related smell loss tested with
294 SCENTinel 1.1. In Parma et al. 2021, the SCENTinel 1.0 classification model accurately

295 predicted individuals with anosmia (N = 111) and normosmia (N = 154) with an area under the
296 curve (AUC) of 0.95 [29], and this same model predicted individuals with anosmia (N = 51) and
297 normosmia (N = 66) in the present sample with an AUC of 0.94 (Figure 1). In other words, the
298 lack of statistical difference between the AUCs of the two tests prospectively validates the
299 original classification model [29] and its ability to extend to olfactory performance related to
300 COVID-19 etiology (current sample). Given that SCENTinel 1.1 includes four odor targets, as
301 compared to one odor target in SCENTinel 1.0, we also assessed whether the different odor
302 targets impacted the ability to identify those with normosmia. There were no significant
303 differences in the average intensity ratings (Bayes Factor giving evidence of H_1 over H_0 (BF_{10}) =
304 0.19) or the overall score (BF_{10} = 0.19) across the four target odor variations of SCENTinel 1.1
305 in individuals with normosmia. The consistency of results across the different study populations
306 from SCENTinel 1.0 [29] and SCENTinel 1.1 (current sample) confirms that the features added
307 to SCENTinel 1.1 (e.g., multiple target odors) still accurately discriminate for self-reported
308 normosmia and anosmia.

309

310 [INSERT FIGURE 1 HERE]

311

312 **SCENTinel 1.1 discriminates between self-reported normosmia, and quantitative and**
313 **qualitative olfactory disorders.**

314 Using a new machine learning classification model that incorporates the features of
315 SCENTinel 1.1 (e.g., hedonic score subtest, multiple odor versions) and aims to predict
316 additional smell disorder groups, the SCENTinel 1.1 overall score model accurately
317 discriminates normosmia (N = 66) and quantitative OD (N = 135) groups (AUC = 0.84; Figure

318 2A), quantitative and qualitative OD (N = 86) groups (AUC = 0.76; Figure 2B) and normosmia
319 and qualitative OD groups (AUC = 0.73; Figure 2C), all at rates significantly better than chance.
320 The SCENTinel 1.1 subtest that best discriminated normosmia, quantitative OD, and qualitative
321 OD groups differed depending on the group comparison. The only subtest that discriminated
322 between quantitative and qualitative OD groups greater than chance was odor intensity (AUC =
323 0.73; Figure 2B), where the qualitative OD group rated the odor intensity higher (67.4 ± 27.4 ;
324 Supplementary Table S2) than the quantitative OD group (44.5 ± 30.0 ; Supplementary Table
325 S2). Normosmia and quantitative OD groups were discriminated by odor intensity (AUC = 0.84)
326 and odor identification (AUC = 0.76) subtests (Figure 2A). The odor identification (AUC =
327 0.73), hedonic score (AUC = 0.71), and odor detection (AUC = 0.70) subtests all discriminated
328 normosmia and qualitative OD groups (Figure 2C). Accuracy rates for all SCENTinel 1.1
329 subtests for each group (i.e., normosmia, quantitative OD, and qualitative OD groups) can be
330 found in Supplementary Table S2.

331

332 [INSERT FIGURE 2 HERE]

333

334 We then used significant findings from the machine learning classification models to
335 determine SCENTinel 1.1 cutoff values for this sample based on Youden's Index [50, 51].
336 Youden's index is defined for all points of a ROC curve, and its maximum value may be used as
337 a criterion for determining the optimal cut-off point [50]. From this sample, rating odor intensity
338 equal to or lower than 56/100 and incorrectly identifying the odor classifies SCENTinel 1.1
339 performance as aligned with that of participants with a self-reported quantitative OD
340 (Supplementary Table S4). Similarly, incorrectly detecting and identifying the odor, and a

341 hedonic score equal to or lower than 20/100 classifies performance at SCENTinel 1.1 as aligned
342 with that of participants with a self-reported qualitative OD (Supplementary Table S4).

343

344 **SCENTinel 1.1 discriminates between self-reported anosmia, hyposmia, parosmia and**
345 **normosmia.**

346 Both quantitative and qualitative OD groups are inherently heterogeneous, and individual
347 olfactory disorders within each group can result in different performance on the SCENTinel 1.1
348 subtests and overall score. For example, within the quantitative OD group, individuals can have a
349 reduced sense of smell (hyposmia) or total smell loss (anosmia). Those with hyposmia are still
350 likely to accurately detect and identify the odor in the SCENTinel 1.1 test, but report a lower
351 odor intensity, whereas those with anosmia would likely not be able to accurately detect or
352 identify an odor on SCENTinel 1.1 without guessing. Given these inherent differences, we
353 determined how performance on SCENTinel 1.1 differentiated the three most common olfactory
354 disorders in our sample: hyposmia (N = 84), anosmia (N = 51), and parosmia (N = 66). The
355 SCENTinel 1.1 overall score accurately predicts group classification - discriminating hyposmia
356 from parosmia (AUC = 0.89), anosmia from parosmia (AUC = 0.82), and hyposmia from
357 anosmia (AUC = 0.78). Accuracy rates for all SCENTinel 1.1 subtests for participants with
358 anosmia, hyposmia, and parosmia can be found in Supplementary Table S2.

359

360 **Self-reported parosmia as captured by SCENTinel 1.1.**

361 We only assessed differences in the hedonic score between those with hyposmia, normosmia,
362 and parosmia. Participants with anosmia were not included in this analysis since rating the
363 pleasantness of an odor by those who cannot perceive it is meaningless. Furthermore, our results

364 confirm that excluding participants with anosmia from this analysis did not significantly
365 contribute to hedonic score differentiation (Supplementary Table S3). As expected, the hedonic
366 score was lowest for those with parosmia compared to those with hyposmia ($t = 3.42, p < 0.001$)
367 and normosmia ($t = 2.06, p = 0.04$; Figure 3A). There was no difference in hedonic score
368 between those with hyposmia and normosmia ($t = 0.48, p = 0.64$). Among those who had
369 parosmia, the majority of participants experienced odor distortions most of the time (Figure 3B).
370 Indeed, hedonic score and parosmia frequency were negatively correlated ($R = -0.21, p <$
371 0.001), such that individuals who experienced parosmia more frequently had a lower hedonic
372 score compared to those who experience parosmia less frequently (Figure 3B). Given that there
373 was no difference in the hedonic score between those with hyposmia and normosmia, and to
374 isolate the effects of parosmia, we combined those with hyposmia and normosmia into one group
375 to compare the hedonic score between those with parosmia ($N = 66$) and those without parosmia
376 ($N = 150$). Coffee is the only odor in SCENTinel 1.1 that is frequently reported to be distorted
377 with parosmia [35,40]. Therefore, we assessed whether there was an effect of the odor used in
378 SCENTinel 1.1 on the hedonic score. There was a significant group effect such that participants
379 with parosmia had lower hedonic scores compared to those without parosmia ($F_{3,285} = 13.78, p <$
380 0.001), but this did not differ between the four odors used in SCENTinel 1.1 ($F_{3,285} = 0.05, p =$
381 0.99 ; Figure 3C). Differences in the hedonic score were primarily driven by a lower pleasantness
382 ratings of the odor in the SCENTinel 1.1 test in those with parosmia ($t = 4.43, p < 0.001$), as
383 opposed to the imagined pleasantness rating of vomit which did not differ between those with
384 and without parosmia ($t = -0.57, p = 0.57$; Figure 3D).
385

386 Discussion

387 Initially developed for population surveillance of smell loss associated with COVID-19,
388 SCENTinel, has been shown to have additional value as an accurate, rapid test that can
389 discriminate the most common olfactory disorders. This proof-of-concept study used SCENTinel
390 1.1, an extended version of SCENTinel 1.0, to discriminate for self-reported quantitative
391 (anosmia or hyposmia) and qualitative (parosmia and/or phantosmia) olfactory disorders. Using
392 one of four odors, each SCENTinel 1.1 version measures odor detection, intensity, identification,
393 and odor pleasantness. The goal of this study was to first validate the ability of SCENTinel 1.1 to
394 discriminate between participants with normosmia and anosmia based on the original model
395 developed with SCENTinel 1.0. The second goal of this study was to investigate whether
396 SCENTinel 1.1 can distinguish between quantitative and qualitative olfactory disorders. The
397 third goal of this study was to assess the ability of the hedonic score to discriminate parosmia.

398 Overall, SCENTinel 1.1 can accurately discriminate between self-reported quantitative
399 OD, qualitative OD, and normosmia groups. Participants were grouped based on a common trait
400 of their self-reported olfactory disorder. Those experiencing diminished perceived odor intensity,
401 like people with anosmia and hyposmia, were grouped as people with quantitative olfactory
402 disorders. Those having distorted odor perceptions, like people with parosmia and phantosmia,
403 were grouped as people with qualitative olfactory disorders. However, we noticed heterogeneity
404 and complexity in SCENTinel 1.1 performance, both in the overall score and on each subtest,
405 within each broad classification of quantitative and qualitative OD. For example, a larger than
406 expected percent of participants in the quantitative OD group accurately detected the odor on the
407 SCENTinel 1.1 test, which may reflect the quantitative OD group predominantly having
408 hyposmia ($84/135 = 62\%$; Figure 4). Despite the heterogeneity, the overall score and subtests of

409 SCENTinel 1.1 still accurately discriminated between normosmia, quantitative OD, and
410 qualitative OD groups with acceptable sensitivity (AUC > 0.7).

411 To reduce the heterogeneity, when we assessed how well individual smell groups
412 performed on SCENTinel 1.1, we found that SCENTinel 1.1 can discriminate between those
413 with anosmia, hyposmia, and parosmia. Despite the smaller sample size, SCENTinel 1.1 was
414 more sensitive at discriminating between anosmia, hyposmia, and parosmia groups than the
415 broad quantitative and qualitative OD group classifications, likely because the individual smell
416 groups are less heterogeneous classifications. Phantosmia was not included because of the
417 limited sample size (N = 9). More research is needed to understand how those with phantosmia
418 perform on SCENTinel. Different SCENTinel 1.1 subtests were able to discriminate between
419 different groups. There was no difference in odor detection, but odor intensity was able to
420 discriminate anosmia from hyposmia, and parosmia. Odor identification and the hedonic score
421 discriminated between hyposmia and parosmia. The present study highlights the complexity of
422 classifying individual olfactory disorders, both quantitative and qualitative alike, with a rapid,
423 self-administered smell test. While we only included individuals with a single olfactory disorder
424 in our analyses, individuals can have a quantitative and qualitative olfactory disorder
425 simultaneously (e.g., hyposmia *and* parosmia), and it is rare to have a single qualitative olfactory
426 disorder alone [3]. One area of future research is to explore these complexities to better classify
427 olfactory disorders using SCENTinel.

428 The SCENTinel 1.1 overall score consistently discriminated between groups at rates
429 significantly better than chance, with a similar or higher accuracy than any subtest. Many other
430 smell tests only use one olfactory function (e.g., summed performance from odor identification)
431 to classify olfactory disorders [19,28]. However, our results show that while incorrectly

432 identifying an odor indicates that someone has an olfactory disorder, more information is needed
433 to determine whether the nature of such disorder is quantitative (indicating olfactory loss) or
434 qualitative (indicating olfactory distortions). Assessing odor detection, intensity, identification,
435 and hedonic score within the SCENTinel 1.1 test provides information about participants'
436 olfactory abilities beyond the usually tested olfactory identification. Measuring different
437 olfactory functions reveals response patterns commonly associated with different etiologies of
438 olfactory disorders [54]. For example, in a group of individuals with hyposmia from various
439 etiologies who completed the Sniffin' Sticks extended test battery (completion time ~45 mins),
440 those with hyposmia from Parkinson's disease performed well on odor threshold tests, but had
441 reduced odor detection and identification ability, likely because of impaired central olfactory
442 information processing. Those with hyposmia from sinonasal disease performed well on odor
443 detection and identification, but had poor olfactory thresholds, likely because of anatomical
444 obstruction, or inflammation and edema [54]. To the best of our knowledge, SCENTinel 1.1 is
445 the only tool that can screen for multiple olfactory functions in less than 5 minutes, and that has
446 the potential to provide etiological insight.

447 Including the hedonic score in SCENTinel 1.1 was successful in discriminating parosmia.
448 As hypothesized, participants with parosmia reported a lower hedonic score compared to
449 participants without parosmia, driven by a lower hedonic rating of the target odor on the
450 SCENTinel card, as the hedonic rating of the imagined vomit odor was not different between
451 participants with and without parosmia. This finding supports reports of individuals with
452 parosmia often finding odors to be unpleasant [39]. However, less commonly, some patient
453 reports have shown a valence flip - in addition to pleasant odors smelling unpleasant, reporting
454 odors typically experienced as foul are now pleasant [31,55,56]. To test this valence flip theory,

455 an actual unpleasant target odor may need to be experienced to capture the less-common
456 negative-to-positive hedonic experience, as our use of an imagined unpleasant odor was not
457 adequate. Furthermore, specific distortions have been reported, coffee being prominently
458 reported in interviews with patients who have parosmia [2,40]. However, we did not find any
459 significant difference in hedonic scores between the flower, coffee, bubblegum, or caramel
460 popcorn odors used in SCENTinel 1.1. Notably, we did not assess individual parosmia triggers in
461 the participants with parosmia, therefore it is unknown if coffee was a specific odor distortion in
462 our current sample. Someone with parosmia may still be able to guess the identity of an odor if
463 they know what their distortion is triggered by (for example, if coffee typically smells like
464 gasoline, and they smell gasoline on the smell test, they might accurately identify the odor as
465 coffee because of the association). Therefore, a hedonic score that assesses pleasantness
466 circumvents this issue of accurately identifying odors that are known distortions. Overall, our
467 findings partially support the rationale to use the hedonic score proposed by Liu et al [27],
468 capturing positive odors smelling negative.

469 More research is needed to account for the impact of varying etiologies of olfactory
470 disorders. Presently, SCENTinel 1.1 accurately predicted group classification in participants who
471 experienced olfactory disorders because of COVID-19, which supports the use of SCENTinel 1.1
472 to understand COVID-19 olfactory symptoms. It also supports the use of SCENTinel 1.1 as a
473 tool to help detect and monitor sudden loss of smell, which is a symptom of COVID-19 [5,57],
474 as well as parosmia, an evolving symptom of COVID-19 [31,36,37]. Early diagnosis of olfactory
475 impairment is critical for establishing successful outcomes to treatment regimens like olfactory
476 training [58] which has recently shown effectiveness with patients with parosmia [59].

477

478 **Limitations**

479 Participants were grouped based on their self-reported olfactory disorders. It is possible
480 that participants did not accurately classify their olfactory disorder [7,60]. To limit inaccurate
481 data, we asked specific questions describing their smell loss (Figure 4) and excluded participants
482 whose self-reported olfactory disorder did not fit conventional categories (i.e. someone who
483 reported having both anosmia and hyposmia). An area of future research is to directly screen for
484 smell function with another validated smell test to better understand how they perform on
485 SCENTinel. Granted, there are no direct, validated tests that diagnose parosmia aside from
486 SCENTinel 1.1. Until then, in-depth interviews would be necessary. Another limitation of this
487 study is that COVID-19 test results were also self-reported. However, participants in this study
488 were recruited from a Facebook group specifically for those with smell loss from COVID-19,
489 and specific questions describing the cause of their smell loss (*In your opinion, what might have
490 been the cause of your smell loss? Selected “COVID-19”*), and their COVID-19 test results
491 [What was the test result? 1) Selected “Positive Lab Test (COVID+)”] were included to
492 eliminate participants who had smell loss unrelated to COVID-19 and reduce heterogeneity.
493 Nevertheless, SCENTinel 1.1 was designed to test for olfactory disorders regardless of the
494 etiology; thus, inaccurate reports of COVID-19 diagnosis are not expected to alter the results.
495 However, this is another area where future studies are needed. Finally, SCENTinel 1.1 uses one
496 of four different odors in each test. Including more odor options, particularly unpleasant odors,
497 may help to better measure and understand parosmia. Not all odors are equally distorted in those
498 who experience parosmia [40]. The four odors used in SCENTinel 1.1 may not have been odors
499 that were distorted in the participants with parosmia.

500

501 **Conclusion**

502 Screening for various olfactory disorders is complex and due to the heterogeneity between and
503 within olfactory disorders, often takes time and specialty expertise. Despite being a rapid,
504 inexpensive, self-administered test, SCENTinel 1.1 can discriminate between those with self-
505 reported normosmia and quantitative (i.e., anosmia or hyposmia), and qualitative (i.e., parosmia
506 and/or phantosmia) olfactory disorders with a high degree of accuracy. By assessing hedonics,
507 SCENTinel is a direct smell test that can rapidly capture self-reported parosmia. SCENTinel may
508 serve as a useful tool in research settings to assess smell function.

509

510 **Competing interests**

511 On behalf of the authors of this manuscript, the Monell Chemical Senses Center and Temple
512 University have been awarded patent protection (US patent no 11,337,640) and this patent has
513 been licensed to Ahersla Health, Inc. The authors may benefit financially through their
514 institution's patent policy.

515

516 **Author contributions**

517 SRH: manuscript writing and reviewing; MEH: conceptualization, pre-registration, data
518 collection, data analysis, manuscript writing and reviewing; RP: data analysis, manuscript
519 writing and reviewing; MAO: conceptualization, revision; NER: revision; DRR:
520 conceptualization, revision; PHD: conceptualization, revision; VP: conceptualization, pre-
521 registration, revision.

522

523 **Funding**

524 We acknowledge support from the National Institutes of Health as part of the RADx-rad
525 initiative (U01 DC019578 to PHD and VP). MEH was supported by NIH T32 (DC000014) and
526 F32 (DC020100) funding during this work; RP was supported by NIH T32 funding (DC000014)
527 and F32 (DC020380).

528

529 **Acknowledgments**

530 This work would not be possible without people who are willing to participate in the research.
531 We are extremely grateful to Chrissi Kelly for bridging researchers and the community of
532 patients with smell loss through the UK-based charity AbScent. With her gracious support, we
533 were able to recruit from AbScent's social media pages. We also wholeheartedly thank the
534 participants - people living with olfactory disorders and allies - for their contribution to the
535 development of SCENTinel, a tool that we hope to put at the service of the whole population.

536

537 **Data Availability**

538 The data and analysis script will be publicly available on OSF upon acceptance of the
539 publication [48].

540

541

542 **References**

- 543 1. Rawal S, Hoffman HJ, Bainbridge KE, Huedo-Medina TB, Duffy VB. Prevalence and
544 risk factors of self-reported smell and taste alterations: results from the 2011-2012 US national
545 health and nutrition examination survey (NHANES). *Chem Senses*. 2016 Jan;41(1):69–76.
- 546 2. Bonfils P, Avan P, Faulcon P, Malinvaud D. Distorted odorant perception: analysis of a
547 series of 56 patients with parosmia. *Arch Otolaryngol Head Neck Surg*. 2005 Feb;131(2):107–
548 12.
- 549 3. Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al.
550 Position paper on olfactory dysfunction. *Rhinology*. 2016 Jan 31;56(1):1–30.
- 551 4. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review.
552 *Chem Senses*. 2014 Mar;39(3):185–94.
- 553 5. Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakke AJ, et al. Recent
554 smell loss is the best predictor of COVID-19 among individuals with recent respiratory
555 symptoms. *Chem Senses* [Internet]. 2020 Dec 25 [cited 2021 Feb 11];(bjaa081). Available from:
556 <https://doi.org/10.1093/chemse/bjaa081>
- 557 6. CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. [cited
558 2022 June 28]. Available from: <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>
- 559 7. Hannum ME, Ramirez VA, Lipson SJ, Herriman RD, Toskala AK, Lin C, et al. Objective
560 sensory testing methods reveal a higher prevalence of olfactory loss in COVID-19–positive
561 patients compared to subjective methods: a systematic review and meta-analysis. *Chem Senses*.
562 2020 Nov 1;45(9):865–74.
- 563 8. Chiesa-Estomba CM, Lechien JR, Radulesco T, Michel J, Sowerby LJ, Hopkins C, et al.
564 Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. *Eur J Neurol*.
565 2020/08/05 ed. 2020 Nov;27(11):2318–21.
- 566 9. Sakalli E, Temirbekov D, Bayri E, Alis EE, Erdurak SC, Bayraktaroglu M. Ear nose
567 throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients. *Am J*
568 *Otolaryngol*. 2020/06/23 ed. 2020;41(6):102622–102622.
- 569 10. Vaira LA, Hopkins C, Petrocelli M, Lechien JR, Chiesa-Estomba CM, Salzano G, et al.
570 Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and
571 prospective study. *J Laryngol Otol*. 2020 Aug;134(8):703–9.
- 572 11. Reiter ER, Coelho DH, Kons ZA, Costanzo RM. Subjective smell and taste changes
573 during the COVID-19 pandemic: Short term recovery. *Am J Otolaryngol*. 2020
574 Dec;41(6):102639.
- 575 12. Moein ST, Hashemian SM, Tabarsi P, Doty RL. Prevalence and reversibility of smell
576 dysfunction measured psychophysically in a cohort of COVID-19 patients. *Int Forum Allergy*
577 *Rhinol*. 2020 Oct;10(10):1127–35.
- 578 13. Vihta K-D, Pouwels KB, Peto TE, Pritchard E, House T, Studley R, et al. Omicron-
579 associated changes in SARS-COV-2 symptoms in the United Kingdom. *Medrxiv*. 2022 Jan
580 1;2022.01.18.22269082.
- 581 14. Ben Killingley, Alex Mann, Mariya Kalinova, Alison Boyers, Niluka Goonawardane, Jie
582 Zhou, et al. Safety, tolerability, and viral kinetics during SARS-cov-2 human challenge. *Nat*
583 *Portf* [Internet]. 2022 Feb 28; Available from: <https://doi.org/10.21203/rs.3.rs-1121993/v1>
- 584 15. Oleszkiewicz A, Kunkel F, Larsson M, Hummel T. Consequences of undetected
585 olfactory loss for human chemosensory communication and well-being. *Philos Trans R Soc*
586 *Lond B Biol Sci*. 2020 Jun 8;375(1800):20190265.

- 587 16. Rawal S, Hoffman HJ, Honda M, Huedo-Medina TB, Duffy VB. The Taste and Smell
588 Protocol in the 2011–2014 US National Health and Nutrition Examination Survey (NHANES):
589 test–retest reliability and validity testing. *Chemosens Percept*. 2015 Sep;8(3):138–48.
- 590 17. Dalton P, Hummel T. Chemosensory function and response in idiopathic environmental
591 intolerance. *Occup Med Phila Pa*. 2000 Sep;15(3):539–56.
- 592 18. Lötsch J, Hummel T. A machine-learned analysis suggests non-redundant diagnostic
593 information in olfactory subtests. *IBRO Rep*. 2019 Jun;6:64–73.
- 594 19. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell
595 Identification Test: a standardized microencapsulated test of olfactory function. *Physiol Behav*.
596 1984 Mar;32(3):489–502.
- 597 20. Doty RL, Marcus A, Lee WW. Development of the 12-Item Cross-Cultural Smell
598 Identification Test(CC-SIT). *The Laryngoscope*. 1996;106(3):353–6.
- 599 21. Kondo H, Matsuda T, Hashiba M, Baba S. A study of the relationship between the T&T
600 olfactometer and the University of Pennsylvania Smell Identification Test in a Japanese
601 population. *Am J Rhinol*. 1998 Oct;12(5):353–8.
- 602 22. Duff K, mcaffrey RJ, Solomon GS. The Pocket Smell Test. *J Neuropsychiatry Clin
603 Neurosci*. 2002 May 1;14(2):197–201.
- 604 23. Choudhury ES, Moberg P, Doty RL. Influences of age and sex on a microencapsulated
605 odor memory test. *Chem Senses*. 2003 Nov 1;28(9):799–805.
- 606 24. Jackman AH, Doty RL. Utility of a three-item smell identification test in detecting
607 olfactory dysfunction. *The Laryngoscope*. 2005 Dec;115(12):2209–12.
- 608 25. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ‘Sniffin’ Sticks’: Olfactory
609 performance assessed by the combined testing of odor identification, odor discrimination and
610 olfactory threshold. *Chem Senses*. 1997 Feb 1;22(1):39–52.
- 611 26. Croy I, Zehner C, Larsson M, Zucco GM, Hummel T. Test–retest reliability and validity
612 of the Sniffin’ TOM Odor Memory Test. *Chem Senses*. 2015 Mar 1;40(3):173–9.
- 613 27. Liu DT, Welge-Lüssen A, Besser G, Mueller CA, Renner B. Assessment of odor hedonic
614 perception: the Sniffin’ sticks parosmia test (ssparot). *Sci Rep*. 2020 Oct 22;10(1):18019.
- 615 28. Dalton P, Doty RL, Murphy C, Frank R, Hoffman HJ, Maute C, et al. Olfactory
616 assessment using the NIH Toolbox. *Neurology*. 2013 Mar 12;80(Issue 11, Supplement 3):S32–6.
- 617 29. Parma V, Hannum ME, O’Leary M, Pellegrino R, Rawson NE, Reed DR, et al.
618 SCENTinel 1.0: development of a rapid test to screen for smell loss. *Chem Senses*. 2021 Mar 27;
619 30. Landis BN, Frasnelli J, Croy I, Hummel T. Evaluating the clinical usefulness of
620 structured questions in parosmia assessment. *The Laryngoscope*. 2010 Aug;120(8):1707–13.
- 621 31. Pellegrino R, Mainland JD, Kelly CE, Parker JK, Hummel T. Prevalence and correlates
622 of parosmia and phantosmia among smell disorders. *Chem Senses*. 2021 Jan 1;46:bjab046.
- 623 32. Nordin S, Brämerson A, Millqvist E, Bende M. Prevalence of parosmia: the Skövde
624 population-based studies. *Rhinology*. 2007 Mar;45(1):50–3.
- 625 33. Leopold D. Distortion of olfactory perception: diagnosis and treatment. *Chem Senses*.
626 2002 Sep;27(7):611–5.
- 627 34. Frasnelli J, Landis BN, Heilmann S, Hauswald B, Hüttenbrink KB, Lacroix JS, et al.
628 Clinical presentation of qualitative olfactory dysfunction. *Eur Arch Oto-Rhino-Laryngol Off J
629 Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg*.
630 2004 Aug;261(7):411–5.
- 631 35. Keller A, Malaspina D. Hidden consequences of olfactory dysfunction: a patient report
632 series. *BMC Ear Nose Throat Disord*. 2013 Jul 23;13:8.

- 633 36. Ohla K, Veldhuizen MG, Green T, Hannum ME, Bakke AJ, Moein ST, et al. Increasing
634 incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss.
635 Medrxiv. 2021 Jan 1;2021.08.28.21262763.
- 636 37. Tognetti A, Thunell E, Olsson MJ, Greilert N, Havervall S, Thålin C, et al. High
637 prevalence of olfactory disorders 18 months after contracting COVID-19. Medrxiv. 2022 Jan
638 1;2022.01.20.22269490.
- 639 38. Said M, Luong T, Jang SS, Davis ME, deconde AS, Yan CH. Clinical factors associated
640 with lower health scores in COVID-19–related persistent olfactory dysfunction. *Int Forum*
641 *Allergy Rhinol* [Internet]. 2022 Jan 15 [cited 2022 Feb 4];n/a(n/a). Available from:
642 <https://doi.org/10.1002/alr.22978>
- 643 39. Deems DA, Doty RL, Settle RG, Moore-Gillon V, Shaman P, Mester AF, et al. Smell and
644 taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste
645 Center. *Arch Otolaryngol Neck Surg*. 1991 May 1;117(5):519–28.
- 646 40. Parker JK, Kelly CE, Smith B, Hopkins C, Gane SB. An analysis of patients’
647 perspectives on qualitative olfactory dysfunction using social media. *JMIR Form Res*. 2021;
- 648 41. Callahan CD, Hinkebein JH. Assessment of anosmia after traumatic brain injury:
649 performance characteristics of the University of Pennsylvania Smell Identification Test. *J Head*
650 *Trauma Rehabil*. 2002 Jun;17(3):251–6.
- 651 42. Callahan CD, Hinkebein J. Neuropsychological significance of anosmia following
652 traumatic brain injury. *J Head Trauma Rehabil*. 1999 Dec;14(6):581–7.
- 653 43. Bratt M, Skandsen T, Hummel T, Moen KG, Vik A, Nordgård S, et al. Frequency and
654 prognostic factors of olfactory dysfunction after traumatic brain injury. *Brain Inj*.
655 2018;32(8):1021–7.
- 656 44. Albers MW, Tabert MH, Devanand DP. Olfactory dysfunction as a predictor of
657 neurodegenerative disease. *Curr Neurol Neurosci Rep*. 2006 Sep;6(5):379–86.
- 658 45. Barresi M, Ciurleo R, Giacoppo S, Foti Cuzzola V, Celi D, Bramanti P, et al. Evaluation
659 of olfactory dysfunction in neurodegenerative diseases. *J Neurol Sci*. 2012 Dec 15;323(1–2):16–
660 24.
- 661 46. Dintica CS, Marseglia A, Rizzuto D, Wang R, Seubert J, Arfanakis K, et al. Impaired
662 olfaction is associated with cognitive decline and neurodegeneration in the brain. *Neurology*.
663 2019 Feb 12;92(7):e700–9.
- 664 47. Lee DY, Lee WH, Wee JH, Kim J-W. Prognosis of postviral olfactory loss: follow-up
665 study for longer than one year. *Am J Rhinol Allergy*. 2014 Sep 1;28(5):419–22.
- 666 48. Hannum M, Parma V, Pellegrino R, Dalton P, Reed D. Distinguishing qualitative smell
667 disorders from quantitative using the SCENTinel test. 2021 Jan 21 [cited 2021 Mar 18];
668 Available from: <https://osf.io/twu4e>
- 669 49. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The redcap
670 consortium: building an international community of software platform partners. *J Biomed*
671 *Inform*. 2019 Jul 1;95:103208.
- 672 50. Ruopp, M. D., Perkins, N. J., Whitcomb, B. W. & Schisterman, E. F. Youden Index and
673 optimal cut-point estimated from observations affected by a lower limit of detection. *Biom. J.*
674 *Biom. Z.* **50**, 419–430 (2008).
- 675 51. Hsieh, J. W., Keller, A., Wong, M., Jiang, R.-S. & Vosshall, L. B. SMELL-S and
676 SMELL-R: Olfactory tests not influenced by odor-specific insensitivity or prior olfactory
677 experience. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 11275–11284 (2017).

- 678 52. Schönbrodt FD, Zehetleitner M, Wagenmakers E-J, Perugini M. Sequential hypothesis
679 testing with Bayes factors: efficiently testing mean differences. *Psychol Methods*.
680 2017;22(2):322–39.
- 681 53. R Core T. R: A language and environment for statistical computing. 2021;
- 682 54. Whitcroft KL, Cuevas M, Haehner A, Hummel T. Patterns of olfactory impairment
683 reflect underlying disease etiology. *The Laryngoscope*. 2017 Feb;127(2):291–5.
- 684 55. Parker JK, Kelly CE, Gane SB. Molecular mechanism of parosmia [Internet].
685 *Otolaryngology*; 2021 Feb [cited 2021 May 13]. Available from:
686 <http://medrxiv.org/lookup/doi/10.1101/2021.02.05.21251085>
- 687 56. Landis BN, Frasnelli J, Hummel T. Euosmia: A rare form of parosmia. *Acta Otolaryngol*
688 (Stockh). 2006 Jan 1;126(1):101–3.
- 689 57. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time
690 tracking of self-reported symptoms to predict potential COVID-19. *Nat Med*. 2020 Jul
691 1;26(7):1037–40.
- 692 58. Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, mccoil ED. Olfactory training
693 for postviral olfactory dysfunction: systematic review and meta-analysis. *Otolaryngol--Head*
694 *Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg*. 2021 Feb;164(2):244–54.
- 695 59. Aldundag A, Yilmaz E, Kesimli MC. Modified olfactory training is an effective
696 treatment method for COVID-19 induced parosmia. *The Laryngoscope* [Internet]. 2022 Mar 7
697 [cited 2022 Mar 15];n/a(n/a). Available from: <https://doi.org/10.1002/lary.30101>
- 698 60. Lechien JR, Cabaraux P, Chiesa-Estomba CM, Khalife M, Hans S, Calvo-Henriquez C,
699 et al. Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-
700 19 patients. *Head Neck*. 2020 Jul;42(7):1583–90.

701 **Figure Captions**

702

703 **Figure 1.** Validation of the original SCENTinel 1.0 classification model. SCENTinel 1.1-
704 discriminated anosmia and normosmia in a COVID-19-related population (teal color; n = 51 with
705 anosmia, 66 with normosmia) were well fitted to the original SCENTinel 1.0 classification
706 model. Melon color refers to the model performance of SCENTinel 1.0 with the original sample
707 (n = 111 with anosmia, 154 with normosmia). False positive and true positive rates corresponds
708 to the performance of the classification model to accurately predict an individual as someone
709 with ‘anosmia’ or someone with ‘normosmia’ based on their SCENTinel results.

710

711 **Figure 2.** Receiver operating characteristic (ROC) curves and statistics on SCENTinel 1.1 scores
712 overall and for single subtests across groups based on the linear discriminant analysis algorithm:
713 (A) individuals with normosmia (n = 66) versus quantitative dysfunction (n = 135); (B)
714 individuals with quantitative dysfunction versus qualitative dysfunction (n = 86); (C) individuals
715 with normosmia versus qualitative dysfunction. Quantitative dysfunction encompasses
716 individuals with anosmia or hyposmia; qualitative dysfunction includes individuals with
717 parosmia and/or phantosmia. Intensity and hedonics are continuous. AUC, area under the curve;
718 p, p-value; D, DeLong’s test for 2 ROC curves; df, degrees of freedom.

719


720 **Figure 3.** Investigation of the hedonic score across individuals with or without parosmia. A)
721 Comparison of average hedonic score across individual smell groups (n = 84 with hyposmia, 66
722 with normosmia, 66 with parosmia). B) Relationship between hedonic score and frequency of
723 parosmia events (determined via participant’s response to “How often have you experienced

724 smells being distorted or don't smell like they used to?"; n = 66). C) Comparison of average
725 hedonic score per odor across those with and without parosmia (n = 150 without parosmia, 66
726 with parosmia). D) Comparison of average hedonic rating and vomit rating across those with and
727 without parosmia. Errors bars indicate standard deviation.


728

729 **Figure 4.** Summary of participants in the current study. Final smell group classifications
730 (quantitative, qualitative, mixed, and normosmia) were based on the self-report answers to the
731 question stated. Quantitative smell disorders are classified as those with a change in the
732 perceived intensity of odors. Qualitative smell disorders include those where the perceptual
733 quality or identity of an odor has changed. Thick-lined and dashed boxes are used in the final
734 analyses.

735




736
737 **Figure 1.** Validation of the original SCENTinel 1.0 classification model. SCENTinel 1.1-
738 discriminated anosmia and normosmia in a COVID-19-related population (n = 51 with
739 anosmia, 66 with normosmia) were well fitted to the original SCENTinel 1.0 classification
740 model. Melon color refers to the model performance of SCENTinel 1.0 with the original sample
741 (n = 111 with anosmia, 154 with normosmia). False positive and true positive rates corresponds
742 to the performance of the classification model to accurately predict an individual as someone
743 with ‘anosmia’ or someone with ‘normosmia’ based on their SCENTinel results.
744




745
 746 **Figure 2.** Receiver operating characteristic (ROC) curves and statistics on SCENTinel 1.1 scores
 747 overall and for single subtests across groups based on the linear discriminant analysis algorithm:
 748 (A) individuals with normosmia (n = 66) versus quantitative dysfunction (n = 135); (B)
 749 individuals with quantitative dysfunction versus qualitative dysfunction (n = 86); (C) individuals
 750 with normosmia versus qualitative dysfunction. Quantitative dysfunction encompasses
 751 individuals with anosmia or hyposmia; qualitative dysfunction includes individuals with
 752 parosmia and/or phantosmia. Intensity and hedonics are continuous. AUC, area under the curve;
 753 p, p-value; D, DeLong's test for 2 ROC curves; df, degrees of freedom.

754
 755
 756
 757



758
759 **Figure 3.** Investigation of the hedonic score across individuals with or without parosmia. A)
760 Comparison of average hedonic score across individual smell groups (N = 84 with hyposmia, 66
761 with normosmia, 66 with parosmia). B) Relationship between hedonic score and frequency of
762 parosmia events (determined via participant's response to "How often have you experienced
763 smells being distorted or don't smell like they used to?"; N = 66). C) Comparison of average
764 hedonic score per odor across those with and without parosmia (N = 150 without parosmia, 66
765 with parosmia). D) Comparison of average hedonic rating and vomit rating across those with and
766 without parosmia. Error bars indicate standard deviation.
767







768
 769 **Figure 4.** Summary of participants in the current study. Final smell group classifications
 770 (quantitative, qualitative, mixed, and normosmia) were based on the self-report answers to the
 771 question stated. Quantitative smell disorders are classified as those with a change in the
 772 perceived intensity of odors. Qualitative smell disorders include those where the perceptual
 773 quality or identity of an odor has changed. Thick-lined and dashed boxes are used in the final
 774 analyses.

775 **Table 1.** SCENTinel 1.1 accuracy matrix: potential response patterns that determine overall score
 776 classification of correct/incorrect.

Response Pattern #	Odor Detection	Odor Intensity (range 1–100)	Odor Identification		Overall Score
			First attempt	Second attempt	
1	Correct	≥ 21	Correct	NA	<i>Correct</i>
2	Correct	≤ 20	Correct	NA	<i>Incorrect</i>
3	Correct	≥ 21	Incorrect	Correct	<i>Correct</i>
4	Correct	≤ 20	Incorrect	Correct	<i>Incorrect</i>
5	Correct	≥ 21	Incorrect	Incorrect	<i>Correct</i>
6	Correct	≤ 20	Incorrect	Incorrect	<i>Incorrect</i>
7	Incorrect	≥ 21	Correct	NA	<i>Correct</i>
8	Incorrect	≤ 20	Correct	NA	<i>Incorrect</i>
9	Incorrect	≥ 21	Incorrect	Correct	<i>Incorrect</i>
10	Incorrect	≤ 20	Incorrect	Correct	<i>Incorrect</i>
11	Incorrect	≥ 21	Incorrect	Incorrect	<i>Incorrect</i>
12	Incorrect	≤ 20	Incorrect	Incorrect	<i>Incorrect</i>

777 Note: # = response pattern number. Odor detection is by a triangle test. “First attempt” is a four-
 778 alternative forced-choice. “Second attempt” is a three-alternative forced choice.
 779







(A) Normosmia vs. Quantitative**(B) Quantitative vs. Qualitative****(C) Normosmia vs. Qualitative**


Overall Odor Detection Odor Intensity Odor Identification Hedonic Score

	<i>Model comparisons</i>			<i>Random model comparisons</i>	
	AUC	Z	p	D (df)	p
Overall	0.84	-	-	4.28 (43.43)	1.88e-5
Detection	0.67	1.69	0.09	1.56 (60.20)	0.12
Intensity	0.84	0	1	4.02 (76.49)	0.0001
Identification	0.76	0.97	0.33	2.94 (74.18)	0.003
Hedonic Score	0.64	2.32	0.02	1.40 (61.96)	0.16

	<i>Model comparisons</i>			<i>Random model comparisons</i>	
	AUC	Z	p	D (df)	p
Overall	0.76	-	-	2.83 (43.43)	0.005
Detection	0.65	1.32	0.19	1.60 (81.16)	0.11
Intensity	0.73	0.45	0.65	2.62 (76.49)	0.009
Identification	0.62	2.09	0.04	1.28 (75.37)	0.20
Hedonic Score	0.66	1.30	0.19	1.67 (74.42)	0.10

	<i>Model comparisons</i>			<i>Random model comparisons</i>	
	AUC	Z	p	D (df)	p
Overall	0.73	-	-	2.33 (43.43)	0.02
Detection	0.70	0.45	0.65	1.92 (46.44)	0.05
Intensity	0.58	1.99	0.05	0.71 (44.44)	0.48
Identification	0.73	0.07	0.94	2.14 (46.49)	0.03
Hedonic Score	0.71	0.39	0.69	1.94 (46.93)	0.05





Exclusion
 Etiology unrelated to COVID-19, N = 19
 Illogical self-report, N = 30
 Self-reported full recovery, N = 2
 Negative COVID-19 test, N = 57
 Undiagnosed smell loss, N = 11
 Incomplete data, N = 12

Thinking about TODAY, are you experiencing any of the following?
Please check all that apply.

- I cannot smell anything (anosmia)
- I can smell odors but they are weaker than usual (hyposmia)
- I can smell strong odors, but they smell differently than they typically smell (parosmia)
- I smell things that aren't there (e.g., smoke smell when there is no fire, phantosmia)
- Other
- No

QUANTITATIVE
 N = 135

Anosmia (n = 51)
 Hyposmia (n = 84)

QUALITATIVE
 N = 86

Parosmia (n = 66)
 Phantosmia (n = 9)
 Parosmia and Phantosmia (n = 11)

MIXED
 N = 94

Anosmia and Phantosmia (n = 3)
 Hyposmia and Parosmia (n = 36)
 Hyposmia and Phantosmia (n = 25)
 Hyposmia, Parosmia and Phantosmia (n = 30)

NORMOSMIA
 N = 66